Regenxbio resumed with an Outperform at Raymond James
Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...
New Hope For Pets In The Fight Against Cancer: Fast, Accurate Diagnoses From Torigen Pharmaceuticals And Proscia
Pathologists at Torigen leverage Proscia’s Concentriq ® to make precise diagnoses from data-rich images containing one of the most detailed and direct profiles of diseases like cancer. The enterprise ...